Biomarin Pharmaceutical Inc
XBER:BM8

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
XBER:BM8
Watchlist
Price: 50.06 EUR -4.06% Market Closed
Market Cap: 9.2B EUR

Intrinsic Value

The intrinsic value of one BM8 stock under the Base Case scenario is 66.32 EUR. Compared to the current market price of 50.06 EUR, Biomarin Pharmaceutical Inc is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BM8 Intrinsic Value
66.32 EUR
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Biomarin Pharmaceutical Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about BM8?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BM8 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Biomarin Pharmaceutical Inc.

Explain Valuation
Compare BM8 to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Recent regulatory hurdles for BioMarin’s gene therapy portfolio, including potential FDA delays for innovative treatments like valoctocogene roxaparvovec for hemophilia A, could significantly slow revenue growth and erode investor confidence.

The high cost and narrow patient base of BioMarin’s enzyme replacement therapies, such as Vimizim and Naglazyme, expose the company to reimbursement pressures, which could be exacerbated by payers pushing back on premium pricing in rare disease markets.

Failure to diversify beyond a few core rare disease franchises increases BioMarin’s vulnerability to competitive threats and patent cliffs, potentially leading to revenue stagnation if pipeline programs fall short of expectations.

Bull Theses

BioMarin’s deep pipeline in rare genetic disorders, including multiple late-stage gene therapy candidates, positions the company as a leader in high-value, underserved orphan markets, with strong prospects for breakthrough designations.

The firm’s proven track record with commercialized products like Vimizim and Palynziq underlines its expertise in navigating complex regulatory pathways for rare diseases, offering a competitive moat in the orphan drug space.

Management’s focus on in-house manufacturing capabilities for gene therapies provides strategic control over the production process, potentially enabling quicker scale-up and higher margins once therapies gain approval.

Show More Less
How do you feel about BMRN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biomarin Pharmaceutical Inc

Current Assets 3.9B
Cash & Short-Term Investments 1.5B
Receivables 790.3m
Other Current Assets 1.6B
Non-Current Assets 3.8B
Long-Term Investments 512.9m
PP&E 1B
Intangibles 429.3m
Other Non-Current Assets 1.8B
Current Liabilities 798.4m
Accounts Payable 389.7m
Accrued Liabilities 354.9m
Other Current Liabilities 53.8m
Non-Current Liabilities 759.7m
Long-Term Debt 596.7m
Other Non-Current Liabilities 163.1m
Efficiency

Free Cash Flow Analysis
Biomarin Pharmaceutical Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Biomarin Pharmaceutical Inc

Revenue
3.1B USD
Cost of Revenue
-577.9m USD
Gross Profit
2.5B USD
Operating Expenses
-1.9B USD
Operating Income
625.3m USD
Other Expenses
-104.9m USD
Net Income
520.4m USD
Fundamental Scores

BM8 Profitability Score
Profitability Due Diligence

Biomarin Pharmaceutical Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Operating Margin is Increasing
Healthy Operating Margin
53/100
Profitability
Score

Biomarin Pharmaceutical Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

BM8 Solvency Score
Solvency Due Diligence

Biomarin Pharmaceutical Inc's solvency score is 96/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
96/100
Solvency
Score

Biomarin Pharmaceutical Inc's solvency score is 96/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BM8 Price Targets Summary
Biomarin Pharmaceutical Inc

Wall Street analysts forecast BM8 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BM8 is 80.14 EUR with a low forecast of 47.88 EUR and a high forecast of 110.42 EUR.

Lowest
Price Target
47.88 EUR
4% Downside
Average
Price Target
80.14 EUR
60% Upside
Highest
Price Target
110.42 EUR
121% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Biomarin Pharmaceutical Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BMRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BMRN Insider Trading
Buy and sell transactions by insiders

BM8 News

Other Videos
What is the Intrinsic Value of one BM8 stock?

The intrinsic value of one BM8 stock under the Base Case scenario is 66.32 EUR.

Is BM8 stock undervalued or overvalued?

Compared to the current market price of 50.06 EUR, Biomarin Pharmaceutical Inc is Undervalued by 25%.

Back to Top